Search results
Results from the WOW.Com Content Network
According to intellectual historian Jan E. Goldstein, the initial introduction of idée fixe as a medical term occurred around 1812 in connection with monomania. [1] The French psychiatrist Jean-Étienne Dominique Esquirol considered an idée fixe – in other words an unhealthy fixation on a single object – to be the principal symptom of monomania. [2]
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Fixation (German: Fixierung) [1] is a concept (in human psychology) that was originated by Sigmund Freud (1905) to denote the persistence of anachronistic sexual traits. [ 2 ] [ 3 ] The term subsequently came to denote object relationships with attachments to people or things in general persisting from childhood into adult life.
The least anxiety-provoking situations are ordered at the bottom of the hierarchy while the most anxiety-provoking situations are at the top. Exposure hierarchies typically consist of 10-15 items and will guide the client’s exposure practices. [1] An abbreviated example of an exposure hierarchy is pictured in Image 1.
Metacognitive therapy (MCT) is a psychotherapy focused on modifying metacognitive beliefs that perpetuate states of worry, rumination and attention fixation. [1] It was created by Adrian Wells [2] based on an information processing model by Wells and Gerald Matthews. [3] It is supported by scientific evidence from a large number of studies. [4] [5]
An anxiolytic (/ ˌ æ ŋ k s i ə ˈ l ɪ t ɪ k, ˌ æ ŋ k s i oʊ-/; also antipanic or anti-anxiety agent) [1] is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety.
Potential explanations include exacerbating cognitive problems that are already common in anxiety disorders, causing or worsening depression and suicidality, [118] [119] disrupting sleep architecture by inhibiting deep stage sleep, [120] withdrawal symptoms or rebound symptoms in between doses mimicking or exacerbating underlying anxiety or ...
A number of researchers have explored HADS data to establish the cut-off points for caseness of anxiety or depression. Bjelland et al (2002) [3] through a literature review of a large number of studies identified a cut-off point of 8/21 for anxiety or depression. For anxiety (HADS-A) this gave a specificity of 0.78 and a sensitivity of 0.9.